Newsbenzinga
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
· Published
Article summary
Mentari Therapeutics secures $200 million in private financing before merging with InMed Pharmaceuticals to fund migraine therapies.
An excerpt from the original article.
Comments —
Loading comments…